Teclistamab Dosing and Adverse Event Prophylaxis Practices
Following a review of recent data from MajesTEC-1 investigating teclistamab, the panel provides clinical insights on dosing and adverse event prophylaxis practices.
EP: 1.The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma
EP: 2.MajesTEC-1: Efficacy and Safety of Teclistamab
Now Viewing
EP: 3.Teclistamab Dosing and Adverse Event Prophylaxis Practices
EP: 4.Clinical Implications of MajesTEC-1
EP: 5.Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Video content above is prompted by the following question(s):
- What factors could contribute to the observed decrease in the onset of new grade ≥3 infections over time, and what are the clinical implications?
Recent Videos
Related Content
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Article
Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
